[ad_1]
Abivax (NASDAQ:ABVX – Free Report) had its price objective hoisted by Lifesci Capital from $45.00 to $101.00 in a report released on Wednesday morning,Benzinga reports. Lifesci Capital currently has an outperform rating on the stock. Lifesci Capital also issued estimates for Abivax’s FY2025 earnings at ($3.64) EPS.
Other research analysts have also recently issued reports about the stock. Leerink Partners set a $74.00 price objective on shares of Abivax and gave the company an “outperform” rating in a report on Wednesday. Citigroup reiterated a “market outperform” rating on shares of Abivax in a report on Friday, July 18th. Guggenheim increased their price objective on shares of Abivax from $50.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday. Piper Sandler increased their price objective on shares of Abivax from $42.00 to $70.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Morgan Stanley upgraded shares of Abivax from an “equal weight” rating to an “overweight” rating and set a $71.00 price objective for the company in a report on Wednesday. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Abivax presently has an average rating of “Buy” and a consensus price target of $80.00.
Read Our Latest Analysis on Abivax
Abivax Price Performance
Abivax stock opened at $66.49 on Wednesday. The firm has a 50 day simple moving average of $11.03 and a 200-day simple moving average of $8.11. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.29. Abivax has a 12-month low of $4.77 and a 12-month high of $72.90.
Institutional Trading of Abivax
Large investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP bought a new stake in Abivax during the fourth quarter worth approximately $144,000. JPMorgan Chase & Co. bought a new stake in Abivax during the fourth quarter worth approximately $5,336,000. GAMMA Investing LLC boosted its stake in Abivax by 373.6% in the 1st quarter. GAMMA Investing LLC now owns 18,831 shares of the company’s stock worth $118,000 after purchasing an additional 14,855 shares during the period. Guggenheim Capital LLC acquired a new position in Abivax in the 4th quarter worth approximately $92,000. Finally, Millennium Management LLC boosted its stake in Abivax by 44.2% in the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock worth $6,816,000 after purchasing an additional 285,542 shares during the period. 47.91% of the stock is currently owned by institutional investors.
Abivax Company Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Recommended Stories
Receive News & Ratings for Abivax Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abivax and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link